Skip to main content

Table 5 Mean receptor densities in midcingulate area 24' of control subjects and progressive supranuclear palsy patients

From: Multireceptor fingerprints in progressive supranuclear palsy

 

Progressive supranuclear palsy vs. control subjects

Progressive supranuclear palsy, frontal vs. nonfrontal presentation

Progressive supranuclear palsy, mild vs. severe tau pathology

Receptor

Control subjects

Patients

p Value

Frontal

Nonfrontal

p Value

Mild

Severe

p Value

AMPA

731 (39)

739 (246)

0.899

681 (216)

785 (271)

0.421

695 (314)

773 (191)

0.546

Kainate

1129 (182)

1138 (150)

0.880

1102 (162)

1166 (144)

0.422

1161 (166)

1120 (145)

0.602

NMDA

1290 (102)

1455 (188)

0.007

1531 (155)

1397 (198)

0.164

1404 (272)

1495 (79)

0.350

mGlu2/3

7932 (1816)

8576 (1960)

0.361

8462 (1215)

8665 (2464)

0.845

8136 (2647)

8918 (1283)

0.448

GABAA

1975 (188)

2125 (241)

0.070

2078 (204)

2162 (272)

0.506

2232 (323)

2042 (112)

0.181

GABAB

4089 (484)

5126 (801)

<0.001

4826 (360)

5360 (982)

0.176

5322 (1155)

4974 (376)

0.406

BZ

2686 (296)

3094 (1028)

0.164

2676 (525)

3419 (1226)

0.158

3567 (1373)

2726 (468)

0.165

pBZ

1698 (227)

2380 (416)

<0.001

2444 (257)

2330 (402)

0.605

2452 (464)

2325 (394)

0.564

M1

621 (62)

505 (175)

0.023

581 (186)

446 (150)

0.131

458 (204)

542 (150)

0.358

M2

277 (43)

306 (43)

0.076

285 (29)

322 (47)

0.094

323 (54)

293 (29)

0.185

M3

1071 (84)

1135 (127)

0.117

1137 (142)

1133 (122)

0.959

1123 (129)

1144 (132)

0.752

nACh

116 (40)

102 (40)

0.325

104 (47)

100 (35)

0.833

111 (38)

94 (41)

0.425

α1

705 (57)

805 (174)

0.042

803 (204)

807 (159)

0.963

802 (195)

808 (167)

0.949

α2

1124 (190)

1288 (220)

0.039

1342 (201)

1246 (237)

0.407

1337 (221)

1250 (225)

0.453

5-HT1A

542 (53)

630 (119)

0.017

660 (99)

606 (133)

0.380

621 (172)

636 (65)

0.817

5-HT2

817 (74)

963 (170)

0.006

999 (192)

934 (158)

0.471

1001 (177)

933 (169)

0.446

D1

125 (22)

143 (25)

0.050

157 (17)

132 (26)

0.050

136 (29)

149 (21)

0.307

D2

71 (17)

92 (41)

0.092

75 (19)

104 (49)

0.165

107 (57)

80 (18)

0.191

A1

1300 (151)

1476 (318)

0.069

1542 (407)

1424 (241)

0.479

1413 (281)

1525 (352)

0.504

A2A

120 (9)

134 (30)

0.089

142 (24)

128 (35)

0.392

133 (38)

134 (26)

0.941

  1. Abbreviations: A 1 Adenosine receptor type 1, A 2A Adenosine receptor type 2A, α 1 Adrenoceptor type 1, α 2 Adrenoceptor type 2, AMPA α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, BZ γ-Aminobutyric acid type A-associated benzodiazepine-binding site, D1 Dopamine receptor type 1, D2 Dopamine receptor type 2, GABA A γ-Aminobutyric acid receptor type A, GABA B γ-Aminobutyric acid receptor type B, 5-HT 1A Serotonin receptor type 1A, 5-HT 2 Serotonin receptor type 2, M 1 , M 2 , M 3 Muscarinic cholinergic receptor types 1, 2, 3, mGlu2/3 Metabotropic glutamate receptor type 2/3, nACh Nicotinic cholinergic receptor of the α4/β2 type, NMDA N-methyl-d-aspartate, pBZ Peripheral benzodiazepine receptor
  2. Absolute densities (SD) in femtomoles per milligram of protein as well as p values for the post hoc tests (significant values are highlighted in boldface type) are provided for each receptor type. Note that although comparison of mild versus severe tau pathology resulted in a nonsignificant omnibus test, results of the post hoc tests are displayed
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193